Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial

What is it about?

Rare solid tumors account for one-quarter of cancers among adults in the United States, but we still lack efficient treatments in many cases. Considering the success of immunotherapy in oncology, we tested this strategy and found that the treatment is safe and has shown encouraging results in some cases.

Featured Image